Carlos Osmon, MD
Hematology & Oncology · Austell, GANPI 1225033640
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (59.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Incyte Corporation at 38.8% of the total. Reporting peaked in 2019 at $8,461 and has fallen 98.6% since, to $122 in 2025.
Across 136 payments — averaging $76.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$4K
- Gilead$2K
- Boehringer Ingelheim$1K
- Daiichi Sankyo Inc.$478
- Seagen Inc.$438
- Genentech USA, Inc.$344
- plus $2K from 28 others
What the payments were for
- Consulting fees$6,20059%
- Speaking & faculty fees$3603%
- Travel & lodging$5836%
- Food & beverage$3,22831%
- Education$721%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 10 | $4,048 |
| Gilead | 1 | $1,700 |
| Boehringer Ingelheim | 3 | $1,245 |
| Daiichi Sankyo Inc. | 7 | $478 |
| Seagen Inc. | 10 | $438 |
| Genentech USA, Inc. | 10 | $344 |
| AbbVie | 14 | $306 |
| Exelixis Inc. | 3 | $267 |
| Merck | 12 | $191 |
| Pfizer | 7 | $161 |
| Beigene USA, Inc. | 1 | $125 |
| Lilly USA, LLC | 6 | $107 |
| Novartis | 5 | $105 |
| Tersera Therapeutics LLC | 3 | $82 |
| AstraZeneca | 4 | $77 |
| Johnson & Johnson | 5 | $76 |
| Amgen | 4 | $75 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $63 |
| GSK | 3 | $61 |
| Sanofi | 3 | $52 |
| Coherus Oncology, Inc. | 3 | $52 |
| Eisai Inc. | 2 | $51 |
| Regeneron Healthcare Solutions, Inc. | 2 | $47 |
| E.r. Squibb & Sons, L.L.C. | 3 | $45 |
| Bristol Myers Squibb | 2 | $45 |
| Foundation Medicine, Inc. | 1 | $33 |
| Dendreon Pharmaceuticals LLC | 1 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $32 |
| Stemline Therapeutics Inc. | 1 | $22 |
| Taiho Oncology, Inc. | 1 | $21 |
| Jazz Pharmaceuticals Inc. | 1 | $21 |
| Fortovia Therapeutics, Inc. | 1 | $18 |
| Puma Biotechnology, Inc. | 1 | $13 |
| Ipsen Biopharmaceuticals, Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,443 in reported general payments places this provider in the 70th percentile of 370 hematology & oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ondansetron Hcl | 13 | $1,550 |
| ValacyclovirValacyclovir Hcl | 12 | $397 |
| Prochlorperazine Maleate | 15 | $140 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Austell
- Kamal MandalapuAustell$30K
- Priya RudolphAthens$745K
- Aron KefelaHiram$591K
- Chandar BhimaniConyers$483K
- Ticiana LealAtlanta$450K
- Steven McCuneMarietta$450K
- Jorge LeguizamoLawrenceville$409K
- Trevor FeinsteinFayetteville$341K
- Jigarkumar ParikhAugusta$267K
- Ajay NookaAtlanta$222K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.